Rezolute/RZLT

$1.68

2.44%
-
1D1W1MYTD1YMAX

About Rezolute

Rezolute, Inc. is a clinical-stage biopharmaceutical company, which is developing therapies for metabolic diseases related to chronic glucose imbalance. The Company’s lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism (HI), an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase III. RZ358 is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat and muscle. Its second clinical asset, RZ402, is an oral plasma kallikrein inhibitor (PKI) being developed as a therapy for the chronic treatment of diabetic macular edema (DME) in Phase II. RZ402 is designed to be a once daily oral therapy for the treatment of DME and unlike the anti-VEGF therapies, RZ402 targets the Kallikrein-Kinin System to address inflammation and vascular leakage.

Ticker

RZLT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Nevan Elam

Employees

51

Headquarters

Redwood city, United States

Rezolute Metrics

BasicAdvanced
$68.16M
Market cap
-
P/E ratio
-$1.11
EPS
1.23
Beta
-
Dividend rate

What the Analysts think about Rezolute

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 4 analysts.
405.95% upside
High $14.00
Low $4.00
$1.68
Current price
$8.50
Average price target

Rezolute Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$0
-
Net income
$-13.9M
-4.14%
Profit margin
0%
-

Rezolute Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 10.99%
QuarterlyAnnual
Q3 23
Q4 23
Q1 24
Q2 24
Q3 24
Actual
-$0.30
-$0.25
-$0.28
-$0.27
-
Expected
-$0.30
-$0.36
-$0.28
-$0.30
-$0.31
Surprise
0%
-29.78%
-0.88%
-10.99%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Rezolute stock

Buy or sell Rezolute stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing